 | |
 | |
| Clinical data | |
|---|---|
| Trade names | Aerospan, Aerobid, Nasalide, Nasarel, others |
| Other names | 6α-Fluoro-11β,16α,17,21-tetrahydroxypregna-1,4-diene-3,20-dione acetone cyclic 16,17-acetal |
| AHFS/ Drugs.com | Inahled:
Monograph Nose: Monograph |
| MedlinePlus | a681048 |
|
Routes of administration | Inhaled, in the nose |
| Drug class | Corticosteroid [1] [2] |
| Pharmacokinetic data | |
| Protein binding | 40% after inhalation |
| Elimination half-life | 1.8 hours |
| Identifiers | |
| |
| Chemical and physical data | |
| Formula | C24H31FO6 |
| Molar mass | 434.504 g·mol−1 |
| 3D model ( JSmol) | |
| |
| |
 
(what is this?)
(verify) | |
Flunisolide, sold under the brand name Aerospan among others, is a steroid used for allergic rhinitis, asthma, and serous otitis media. [2] [1] Intranasal steroids are the most effective medication for controlling of allergic rhinitis. [3] For asthma it is inhaled. [2]
When used in the nose common side effects include stinging, nose bleed, watery eyes, and upper respiratory tract infection. [1] When inhaled common symptoms include throat inflammation, runny nose, headache, and cough. [2] Other side effects may include loss of smell and adrenal suppression. [1] It has strong glucocorticoid and weak mineralocorticoid effects and works by decreasing inflammation. [1] [2]
Flunisolide was patented in 1958 and approved for medical use in 1978. [4] It is on the World Health Organization's List of Essential Medicines as an alternative to budesonide. [5] In the United States 25 ml of solution to spray in the nose costs about 26 USD, while 60 doses for inhaling costs about 102 USD as of 2021. [6] [7]
References
- ^ a b c d e f g "Flunisolide (EENT) Monograph for Professionals". Drugs.com. Archived from the original on 7 April 2016. Retrieved 11 December 2021.
- ^ a b c d e f g "Flunisolide Monograph for Professionals". Drugs.com. Archived from the original on 15 April 2017. Retrieved 11 December 2021.
- ^ Wallace DV, Dykewicz MS, Bernstein DI, Blessing-Moore J, Cox L, Khan DA, et al. (August 2008). "The diagnosis and management of rhinitis: an updated practice parameter". The Journal of Allergy and Clinical Immunology. 122 (2 Suppl): S1-84. doi: 10.1016/j.jaci.2008.06.003. PMID 18662584.
- ^ Fischer J, Ganellin CR (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 486. ISBN 9783527607495. Archived from the original on 2021-08-28. Retrieved 2020-10-19.
- ^ World Health Organization (2023). The selection and use of essential medicines 2023: web annex A: World Health Organization model list of essential medicines: 23rd list (2023). Geneva: World Health Organization. hdl: 10665/371090. WHO/MHP/HPS/EML/2023.02.
- ^ "Flunisolide Prices, Coupons & Savings Tips - GoodRx". GoodRx. Archived from the original on 9 July 2020. Retrieved 12 December 2021.
- ^ "Aerospan HFA Prices, Coupons & Patient Assistance Programs". Drugs.com. Retrieved 12 December 2021.
|
| |
|
| |
| Clinical data | |
|---|---|
| Trade names | Aerospan, Aerobid, Nasalide, Nasarel, others |
| Other names | 6α-Fluoro-11β,16α,17,21-tetrahydroxypregna-1,4-diene-3,20-dione acetone cyclic 16,17-acetal |
| AHFS/ Drugs.com | Inahled:
Monograph Nose: Monograph |
| MedlinePlus | a681048 |
|
Routes of administration | Inhaled, in the nose |
| Drug class | Corticosteroid [1] [2] |
| Pharmacokinetic data | |
| Protein binding | 40% after inhalation |
| Elimination half-life | 1.8 hours |
| Identifiers | |
| |
| Chemical and physical data | |
| Formula | C24H31FO6 |
| Molar mass | 434.504 g·mol−1 |
| 3D model ( JSmol) | |
| |
| |
|
(what is this?)
(verify) | |
Flunisolide, sold under the brand name Aerospan among others, is a steroid used for allergic rhinitis, asthma, and serous otitis media. [2] [1] Intranasal steroids are the most effective medication for controlling of allergic rhinitis. [3] For asthma it is inhaled. [2]
When used in the nose common side effects include stinging, nose bleed, watery eyes, and upper respiratory tract infection. [1] When inhaled common symptoms include throat inflammation, runny nose, headache, and cough. [2] Other side effects may include loss of smell and adrenal suppression. [1] It has strong glucocorticoid and weak mineralocorticoid effects and works by decreasing inflammation. [1] [2]
Flunisolide was patented in 1958 and approved for medical use in 1978. [4] It is on the World Health Organization's List of Essential Medicines as an alternative to budesonide. [5] In the United States 25 ml of solution to spray in the nose costs about 26 USD, while 60 doses for inhaling costs about 102 USD as of 2021. [6] [7]
References
- ^ a b c d e f g "Flunisolide (EENT) Monograph for Professionals". Drugs.com. Archived from the original on 7 April 2016. Retrieved 11 December 2021.
- ^ a b c d e f g "Flunisolide Monograph for Professionals". Drugs.com. Archived from the original on 15 April 2017. Retrieved 11 December 2021.
- ^ Wallace DV, Dykewicz MS, Bernstein DI, Blessing-Moore J, Cox L, Khan DA, et al. (August 2008). "The diagnosis and management of rhinitis: an updated practice parameter". The Journal of Allergy and Clinical Immunology. 122 (2 Suppl): S1-84. doi: 10.1016/j.jaci.2008.06.003. PMID 18662584.
- ^ Fischer J, Ganellin CR (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 486. ISBN 9783527607495. Archived from the original on 2021-08-28. Retrieved 2020-10-19.
- ^ World Health Organization (2023). The selection and use of essential medicines 2023: web annex A: World Health Organization model list of essential medicines: 23rd list (2023). Geneva: World Health Organization. hdl: 10665/371090. WHO/MHP/HPS/EML/2023.02.
- ^ "Flunisolide Prices, Coupons & Savings Tips - GoodRx". GoodRx. Archived from the original on 9 July 2020. Retrieved 12 December 2021.
- ^ "Aerospan HFA Prices, Coupons & Patient Assistance Programs". Drugs.com. Retrieved 12 December 2021.